MaxCyte, Inc.

NasdaqGS:MXCT Stock Report

Market Cap: US$170.7m

MaxCyte Management

Management criteria checks 1/4

MaxCyte's CEO is Maher Masoud, appointed in Jan 2024, has a tenure of 1.92 years. total yearly compensation is $3.61M, comprised of 16.3% salary and 83.7% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $280.00K. The average tenure of the management team and the board of directors is 1.9 years and 3.8 years respectively.

Key information

Maher Masoud

Chief executive officer

US$3.6m

Total compensation

CEO salary percentage16.34%
CEO tenure1.9yrs
CEO ownership0.2%
Management average tenure1.9yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price

Mar 15

MaxCyte expands capacity by relocating to new HQ in Maryland

Sep 21

MaxCyte signs strategic platform with LG Chem

Jul 12

MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile

Sep 06

CEO Compensation Analysis

How has Maher Masoud's remuneration changed compared to MaxCyte's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$46m

Jun 30 2025n/an/a

-US$45m

Mar 31 2025n/an/a

-US$42m

Dec 31 2024US$4mUS$590k

-US$41m

Sep 30 2024n/an/a

-US$36m

Jun 30 2024n/an/a

-US$35m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$890kUS$450k

-US$38m

Sep 30 2023n/an/a

-US$37m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$791kUS$413k

-US$24m

Compensation vs Market: Maher's total compensation ($USD3.61M) is above average for companies of similar size in the US market ($USD1.47M).

Compensation vs Earnings: Maher's compensation has increased whilst the company is unprofitable.

CEO

Maher Masoud (50 yo)

1.9yrs
Tenure
US$3,611,298
Compensation

Mr. Maher Masoud is President, CEO & Executive Director of MaxCyte, Inc. since January 1, 2024 and served as its Head of Global Business Development and Legal Officer since November 2023 and had been its S...

Leadership Team

NamePositionTenureCompensationOwnership
Maher Masoud
President1.9yrsUS$3.61m0.16%
$ 280.0k
Douglas Swirsky
Chief Financial Officer2.8yrsUS$1.69m0.059%
$ 101.4k
Jay Gelfman
Senior Vice President of Operations1.9yrsno datano data
Jack Horgan
Senior Vice President of Corporate Development2.2yrsno datano data
Ana-Paula Fernandes
Senior Vice President of Global Salesless than a yearno datano data
Jill Mayer
Senior Vice President of Human Resources1.8yrsno datano data
1.9yrs
Average Tenure

Experienced Management: MXCT's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Maher Masoud
President1.9yrsUS$3.61m0.16%
$ 280.0k
William Brooke
Independent Non-Executive Director21.8yrsUS$267.49k0.11%
$ 194.7k
Patrick Balthrop
Independent Non-Executive Director3.1yrsUS$254.99k0.020%
$ 34.2k
Richard Douglas
Independent Non-Executive Chairman of the Board7.8yrsUS$289.99k0.19%
$ 322.2k
Stanley Erck
Independent Non-Executive Director20.8yrsUS$262.49k0.35%
$ 590.6k
John Johnston
Independent Non-Executive Director9.9yrsUS$249.99k0.13%
$ 227.1k
Yasir Al-Wakeel
Independent Non-Executive Director4.5yrsUS$249.99k0.020%
$ 34.2k
Rekha Hemrajani
Independent Non-Executive Director4.5yrsUS$264.99k0.010%
$ 17.1k
Marcela Maus
Member of Scientific Advisory Board2.8yrsno datano data
Cenk Sumen
Member of Scientific Advisory Board1.9yrsUS$897.25kno data
Oliver Rando
Member of Scientific Advisory Board2.8yrsno datano data
Avery Posey
Member of Scientific Advisory Board2.8yrsno datano data
3.8yrs
Average Tenure
61yo
Average Age

Experienced Board: MXCT's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/24 16:31
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MaxCyte, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
Matthew HewittCraig-Hallum Capital Group LLC
Julie SimmondsPanmure Liberum